Immutep Stock Plummets 80% on Failed Cancer Trial

Immutep Shares Collapse After Trial Discontinuation

Immutep Limited (NASDAQ:IMMP) shares plunged by 80% following the company's announcement to halt its TACTI-004 Phase III trial. The decision came after a futility analysis of the study involving its lead drug candidate, eftilagimod alfa.

Trial Halted by Independent Committee

The Independent Data Monitoring Committee (IDMC) recommended stopping the trial, which evaluated eftilagimod alfa in patients with first-line non-small cell lung cancer. The committee determined the study should be discontinued for futility based on available safety and efficacy data.

Market Impact and Analyst Downgrades

In response to the news, analysts have swiftly revised their ratings. Baird downgraded Immutep from Outperform to Neutral, slashing the price target to $1.00 from $7.00. Citizens also downgraded the stock to Market Perform. Despite the setback, the company's cash runway is now expected to extend beyond the second quarter of 2027.

Future Outlook

Immutep will conduct a comprehensive review of the trial data to determine the next steps for its program. While clinical trials in other indications are ongoing, analysts anticipate the stock will trade in line with the market until new significant study results are available.

FAQ

Q: Why did Immutep's stock price drop significantly?
A: The stock plunged 80% after the company halted its Phase III clinical trial for a lung cancer drug due to a determination of futility.

Q: What was the trial studying?
A: The TACTI-004 trial was evaluating the drug eftilagimod alfa for patients with first-line non-small cell lung cancer.

Source: Investing.com